drugset / Trial / NCT06895733
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The efficacy and safety of Pazopanib combined with Palbociclib in the third line and above treatment of refractory solid tumors co amplified in the 11q13 region (FGF3/4/19/CCND1).
Timeline
- Start
- 2024-11-27
- Primary completion
- 2025-12-01
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palbociclib | Small molecule | — | Oral |
| Subject | Pazopanib | Small molecule | 100 mg | Oral |